Skip to main content


Generic name: enasidenib [ EN-a-SID-a-nib ]
Brand name: Idhifa
Dosage form: oral tablet (100 mg; 50 mg)
Drug class: Miscellaneous antineoplastics

Medically reviewed by on Jun 3, 2021. Written by Cerner Multum.

What is enasidenib?

Enasidenib is used to treat acute myeloid leukemia (AML) in adults with an IDH2 mutation. enasidenib is used when AML has come back or has not improved with prior treatment.

Enasidenib may also be used for purposes not listed in this medication guide.


Seek medical help right away if you have symptoms of differentiation syndrome within 10 days to 5 months after taking enasidenib. Symptoms include fever, cough, trouble breathing, bone pain, rapid weight gain, or swelling in your arms, legs, underarms, groin, or neck.

Before taking this medicine

You may need to have a negative pregnancy test before starting this treatment.

Both men and women using enasidenib should use birth control to prevent pregnancy. Enasidenib can harm an unborn baby if the mother or father is using this medicine.

Keep using birth control for at least 2 months after your last dose. Tell your doctor right away if a pregnancy occurs.

Do not breastfeed while using this medicine, and for at least 2 months after your last dose.

How should I take enasidenib?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.

Drink plenty of liquids while you are taking enasidenib.

Take with or without food, at the same time each day

Do not crush, chew, or break an enasidenib tablet. Swallow it whole.

If you vomit shortly after taking enasidenib, do not take another dose. Take your next dose as scheduled.

You may need frequent medical tests and your cancer treatments may be delayed based on the results.

Store at room temperature away from moisture and heat. Keep the tablets in their original container, along with the canister of moisture-absorbing preservative.

What happens if I miss a dose?

Take the missed dose on the same day you remember it. Take your next dose at the regular time and stay on your once-daily schedule. Do not use 2 doses in one day.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking enasidenib?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Enasidenib side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Enasidenib can cause a condition called differentiation syndrome, which affects blood cells and can be fatal if not treated. This condition may occur within 10 days to 5 months after you start taking enasidenib.

Seek medical help right away if you have symptoms of differentiation syndrome:

  • fever, cough, trouble breathing;

  • bone pain;

  • rapid weight gain; or

  • swelling in your arms, legs, underarms, groin, or neck.

Call your doctor at once if you have any of these side effects:

  • dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);

  • severe or ongoing vomiting or diarrhea; or

  • signs of tumor cell breakdown--tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.

Common side effects of enasidenib may include:

  • nausea, vomiting, diarrhea;

  • loss of appetite; or

  • jaundice.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Enasidenib dosing information

Usual Adult Dose for Acute Myeloid Leukemia:

100 mg orally once a day with or without food

Duration of Therapy:
-Treat until disease progression or unacceptable toxicity.
-For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.

Comments: Select patients based on the presence of isocitrate dehydrogenase-2 (IDH2) mutations in the blood or bone marrow as detected by an FDA-approved test,

Use: Treatment of relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.

What other drugs will affect enasidenib?

Other drugs may affect enasidenib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Popular FAQ

Idhifa (enasidenib) is an oral medicine used to treat adults with acute myeloid leukemia (AML) and specific genetic mutation known as IDH2 (isocitrate dehydrogenase-2). Idhifa is used in patients with AML that has returned after initial treatment (relapsed) or has not responded to treatment (refractory). Continue reading

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.